Neos Theraps Company Profile
What is the competitive landscape for NEOS THERAPS
NEOS THERAPS has four approved drugs.
There are eight US patents protecting NEOS THERAPS drugs.
Summary for Neos Theraps
| US Patents: | 8 |
| Tradenames: | 4 |
| Ingredients: | 3 |
| NDAs: | 4 |
Drugs and US Patents for Neos Theraps
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-006 | Jan 27, 2016 | AB | RX | Yes | Yes | 8,840,924 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-004 | Jan 27, 2016 | AB | RX | Yes | No | 8,709,491 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Neos Theraps Inc | COTEMPLA XR-ODT | methylphenidate | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 205489-004 | Aug 19, 2024 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-002 | Jan 27, 2016 | AB | RX | Yes | No | 8,840,924 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-004 | Jan 27, 2016 | AB | RX | Yes | No | 9,265,737 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Neos Theraps
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-006 | Jan 27, 2016 | 8,840,924 | ⤷ Start Trial |
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-005 | Jan 27, 2016 | 8,840,924 | ⤷ Start Trial |
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-003 | Jan 27, 2016 | 8,840,924 | ⤷ Start Trial |
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-001 | Jan 27, 2016 | 8,840,924 | ⤷ Start Trial |
| Neos Theraps Inc | COTEMPLA XR-ODT | methylphenidate | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 205489-001 | Jun 19, 2017 | 8,840,924 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Neos Theraps Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20240033130 | ⤷ Start Trial |
| European Patent Office | 3585439 | ⤷ Start Trial |
| European Patent Office | 2726066 | ⤷ Start Trial |
| Japan | 2020504763 | ⤷ Start Trial |
| European Patent Office | 2726066 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
